Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Equities researchers at HC Wainwright increased their Q3 2026 earnings estimates for shares of Pharming Group in a research note issued on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.23 per share for the quarter, up from their prior forecast of $0.20. HC Wainwright has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group's current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Pharming Group's Q4 2026 earnings at $0.24 EPS.
Several other research firms also recently weighed in on PHAR. Zacks Research downgraded Pharming Group from a "hold" rating to a "strong sell" rating in a report on Friday, July 31st. Oppenheimer reiterated an "outperform" rating on shares of Pharming Group in a report on Thursday, July 30th. Weiss Ratings reissued a "sell (d)" rating on shares of Pharming Group in a research report on Friday, August 7th. Finally, Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a report on Wednesday, September 23rd. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Pharming Group has a consensus rating of "Hold" and a consensus price target of $38.67.
Read Our Latest Research Report on Pharming Group
Pharming Group Price Performance
Shares of PHAR stock opened at $9.99 on Thursday. Pharming Group has a twelve month low of $9.62 and a twelve month high of $21.34. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. The stock has a fifty day simple moving average of $11.27 and a two-hundred day simple moving average of $13.34. The stock has a market capitalization of $707.09 million, a price-to-earnings ratio of 83.25 and a beta of 0.01.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.
Institutional Investors Weigh In On Pharming Group
An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group makes up approximately 6.0% of MAC Alpha Capital Management LP's investment portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission (SEC). 0.03% of the stock is currently owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.
Pharming's principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
